Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE002 (USA) (Dr. Nolan)
· consented 2022-10-01
Adverse events
6
Serious AEs
0
Open data queries
0
Luna dropout signal
–
Adverse events
moderate
assessed
2026-08-18
Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-10-15 (study day 4); relationship: N
mild
assessed
2026-08-18
Grade 1 Hypothyroidism — outcome: RECOVERED/RESOLVED; onset 2023-01-19 (study day 100); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-03-22 (study day 162); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-03-24 (study day 164); relationship: N
mild
assessed
2026-08-18
Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-07-23 (study day 285); relationship: N
moderate
assessed
2026-08-18
Grade 2 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-08-14 (study day 307); relationship: not assessed
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.